Evidence map›Paper›PMID 41611675›Full record

ArticleNature communications2026

IFITM3 deficiency drives SARS-CoV-2 adaptation while preserving variant-specific traits.

Parker J Denz, Samuel Speaks, Matthew I McFadden, Jana M Cable, Ahmed K Aladhami, Jonathan L Papa, Rachael E Rayner, Prerana R Rao, Steve Leumi, Jack E Roettger and 4 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Parker J DenzDepartment of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, USA.ORCID http://orcid.org/0000-0001-9420-1337
Samuel SpeaksDepartment of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, USA.ORCID http://orcid.org/0009-0003-7610-1502
Matthew I McFaddenDepartment of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, USA.
Jana M CableDepartment of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, USA.
Ahmed K AladhamiDepartment of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, USA.
Jonathan L PapaDepartment of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, USA.
Rachael E RaynerDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH, USA.ORCID http://orcid.org/0000-0002-0659-559X
Prerana R RaoDepartment of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, USA.
Steve LeumiDepartment of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, USA.
Jack E RoettgerDepartment of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, USA.ORCID http://orcid.org/0009-0006-7584-3020
Miqdad O DhariwalaDepartment of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, USA.
Estelle Cormet-BoyakaDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH, USA.ORCID http://orcid.org/0000-0001-9839-384X
Adriana ForeroDepartment of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, USA. Adriana.Forero@osumc.edu.ORCID http://orcid.org/0000-0002-2698-658X
Jacob S YountDepartment of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, USA. Jacob.Yount@osumc.edu.ORCID http://orcid.org/0000-0002-6128-4575

Funding

Identification of novel type III IFN regulatory pathwaysR35GM150806 · NIGMS · OHIO STATE UNIVERSITY · PI Adriana Forero · 2023 to 2026
$1.6M
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID) AI130110NIGMS NIH HHS R35 GM150806U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL154001U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL157215U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL168501
6 · The paper itself

Abstract

SARS-CoV-2 can infect and adapt to multiple animal species, yet the host determinants that control interspecies viral adaptation remain poorly defined. Here we investigate whether interferon-induced transmembrane protein 3 (IFITM3), a key antiviral protein deficient in certain human populations, affects interspecies adaptation of SARS-CoV-2. We find that SARS-CoV-2 Beta and Omicron BA.4 variants passaged through IFITM3-deficient versus wild type mice exhibit enhanced replication and pathogenesis in this new host species. These enhancements are associated with amino acid substitutions in the viral genome, suggesting that IFITM3 limits accumulation of adaptive mutations. Mouse-adapted viruses enable comparative studies of variants in mice. Beta causes lung dysfunction and alters cilia-associated gene programs, consistent with broad viral antigen distribution in the lungs. Omicron, which shows mild pathogenicity and upper respiratory tract preference in humans, replicates to high nasal titers while exhibiting limited lung spread and reduced inflammatory responses compared to Beta. Our findings demonstrate that IFITM3 deficiency accelerates SARS-CoV-2 adaptation while preserving pre-existing variant-specific properties, highlighting that host adaptation enhances viral fitness without necessarily overriding intrinsic viral characteristics.

Indexed as

COVID-19Membrane ProteinsRNA-Binding ProteinsSARS-CoV-2AnimalsFemaleGenome, ViralHumansLungMiceMice, KnockoutMutationVirus Replicationfragilis protein, mouseIFITM3 protein, humanMembrane ProteinsRNA-Binding Proteins

Identifiers

PMID41611675
PMCPMC12917256

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.